Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

NCT04376866

PHASE3INTERVENTIONAL

Cancer Hospital of Guangxi Medical University

204 participants

Started 2020-06-28 · Completed 2028-04

Status: Recruiting (as of 12-23-2025)

Conditions

Recurrent Nasopharyngeal Carcinoma

Interventions

DRUG: Toripalimab

Linked Papers (from SciSciNet-V2)

Total Papers20

Background

10

Result

0

Derived

0

Unknown

10

View on ClinicalTrials.gov

Total Citations Per Year

Brief Summary

This is a phase 3, multicentre, randomised controlled trial to study the effectiveness and toxicity of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy versus cisplatin concurrent chemoradiotherapy alone in treating patients with locoregionally recurrent nasopharyngeal carcinoma.

Sort by:

Background Papers20

The blockade of immune checkpoints in cancer immunotherapy

12,062 citations

The blockade of immune checkpoints in cancer immunotherapy

12,062 citations

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

7,844 citations

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

7,844 citations

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

4,139 citations

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

4,139 citations

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

Intensity-Modulated Radiation Therapy With or Without Chemotherapy for Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225

Intensity-Modulated Radiation Therapy With or Without Chemotherapy for Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy

Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial

Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial

Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials

Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials

Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma

Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma

Result Papers0

No result papers linked

Derived Papers0

No derived papers linked

Unknown Papers10

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

74,955 citations

PD-1 and Its Ligands in Tolerance and Immunity

4,838 citations

Restoring function in exhausted CD8 T cells during chronic viral infection

3,743 citations

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

2,746 citations

How Does Intensity-Modulated Radiotherapy Versus Conventional Two-Dimensional Radiotherapy Influence the Treatment Results in Nasopharyngeal Carcinoma Patients?

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma

B7-H1 pathway and its role in the evasion of tumor immunity

Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy

Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma